Online citations, reference lists, and bibliographies.
← Back to Search

Assessment Of Vertebral Fracture Risk And Therapeutic Effects Of Alendronate In Postmenopausal Women Using A Quantitative Computed Tomography-based Nonlinear Finite Element Method

K. Imai, I. Ohnishi, T. Matsumoto, S. Yamamoto, K. Nakamura
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
SummaryA QCT-based nonlinear FEM was used to assess vertebral strength and mechanical parameters in postmenopausal women. It had higher discriminatory power for vertebral fracture than aBMD and vBMD. Alendronate effects were detected at 3 months, and marked bone density increases were noted in juxta-cortical areas compared to inner trabecular areas.IntroductionQCT-based finite element method (QCT/FEM) can predict vertebral compressive strength ex vivo. This study aimed to assess vertebral fracture risk and alendronate effects on osteoporosis in vivo using QCT/FEM.MethodsVertebral strength in 104 postmenopausal women was analyzed, and the discriminatory power for vertebral fracture was assessed cross-sectionally. Alendronate effects were also prospectively assessed in 33 patients with postmenopausal osteoporosis who were treated with alendronate for 1 year.ResultsOn the age and body weight adjusted logistic regression, vertebral strength had stronger discriminatory power for vertebral fracture (OR per SD change: 6.71) than areal BMD and volumetric BMD. The optimal point for the vertebral fracture threshold was 1.95 kN with 75.9% sensitivity and 78.7% specificity. At 3 months, vertebral strength significantly increased by 10.2% from baseline. The minimum principal strain distribution showed that the area of high fracture risk decreased. At 1 year, the density of the inner cancellous bone increased by 8.3%, while the density of the juxta-cortical area increased by 13.6%.ConclusionsQCT/FEM had higher discriminatory power for vertebral fracture than BMD and detected alendronate effects at 3 months. Alendronate altered density distributions, thereby decreasing the area with a high fracture risk, resulting in increased vertebral strength.
This paper references
10.1118/1.598629
Measurement of thickness and density of thin structures by computed tomography: a simulation study.
G. Dougherty (1999)
10.1016/8756-3282(95)00436-X
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.
J. Devogelaer (1996)
Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.
L. Alexeeva (1994)
10.1359/jbmr.1997.12.10.1721
Prediction of Vertebral Strength In Vitro by Spinal Bone Densitometry and Calcaneal Ultrasound
X. Cheng (1997)
10.1097/BRS.0b013e31815e3993
In Vivo Assessment of Lumbar Vertebral Strength in Elderly Women Using Computed Tomography-Based Nonlinear Finite Element Model
K. Imai (2008)
10.1016/J.BONE.2006.10.025
Comparison of quantitative computed tomography-based measures in predicting vertebral compressive strength.
J. Buckley (2007)
10.1016/J.JBIOMECH.2006.08.003
Prediction of strength and strain of the proximal femur by a CT-based finite element method.
M. Bessho (2007)
10.1002/JBMR.5650090514
Improved assessment of lumbar vertebral body strength using supine lateral dual‐energy X‐ray absorptiometry
B. Myers (1994)
10.1002/JOR.1100160305
Computed tomography‐based finite element analysis predicts failure loads and fracture patterns for vertebral sections
M. Silva (1998)
10.1016/S0140-6736(96)07088-2
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
D. Black (1996)
10.7326/0003-4819-122-7-199504010-00024
Reviews and Notes: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis
L. Alexeeva (1995)
10.1097/01.brs.0000225993.57349.df
Nonlinear Finite Element Model Predicts Vertebral Bone Strength and Fracture Site
K. Imai (2006)
10.1007/s00198-004-1736-9
Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naïve postmenopausal women
Kuo-Chiang Lian (2004)
10.1359/jbmr.061011
Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis
T. M. Keaveny (2007)
10.1016/S1350-4533(01)00045-5
Improved prediction of proximal femoral fracture load using nonlinear finite element models.
J. Keyak (2001)
mass of the spine , hip , and total body over 3 years in postmenopausal women with osteoporosis
Tucci (1996)
10.1016/J.JBIOMECH.2006.05.007
Bone remodelling algorithms incorporating both strain and microdamage stimuli.
L. McNamara (2007)
10.1056/NEJMOA031975
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis.
D. Black (2003)
10.1016/S1350-4533(01)00094-7
Prediction of fracture location in the proximal femur using finite element models.
J. Keyak (2001)
10.1007/BF01626536
Anteroposterior and lateral spinal DXA for the assessment of vertebral body strength: Comparison with hip and forearm measurement
K. Bjarnason (2005)
10.1016/S0021-9290(97)00123-1
Prediction of femoral fracture load using automated finite element modeling.
J. Keyak (1998)
10.1359/jbmr.070728
Structural Determinants of Vertebral Fracture Risk
L. J. Melton (2007)
10.1016/S8756-3282(01)00485-9
Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women.
P. Roschger (2001)
10.1001/ARCHINTE.165.15.1762
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass.
M. Mcclung (2005)
Osteoporosis prevention, diagnosis, and therapy.
A. Klibanski (2000)
10.1097/01.BRS.0000049923.27694.47
Finite Element Modeling of the Human Thoracolumbar Spine
M. Liebschner (2003)
10.1148/RADIOLOGY.179.3.2027972
Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis.
K. Faulkner (1991)
10.1016/S8756-3282(03)00210-2
Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography.
R. Crawford (2003)
10.1097/00006254-199604000-00018
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal Osteoporosis
U. Liberman (1996)
10.1016/S8756-3282(00)00376-8
Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women.
G. Boivin (2000)
10.1088/0031-9155/44/3/017
Accuracy limits for the determination of cortical width and density: the influence of object size and CT imaging parameters.
S. Prevrhal (1999)
10.1001/jama.285.6.785
Osteoporosis prevention, diagnosis, and therapy.
Leo Lutwak (2001)
10.1002/JBM.B.30341
Mechanical evaluation of bone samples following alendronate therapy in healthy male dogs.
K. Fischer (2006)
10.1515/bmte.1998.43.4.82
Noninvasive Assessment of Stiffness and Failure Load of Human Vertebrae from CT-Data. Nichtinvasive Abschätzung von Steifigkeit und Versagenslast von osteoporotischen Wirbelkörpern nach CT-Daten
H. Martin (1998)
10.1001/ARCHINTE.1997.00440430099012
Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
K. Ensrud (1997)
10.1016/S0002-9343(01)01124-X
Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.
S. Cummings (2002)
10.1007/s007740170001
Diagnostic criteria for primary osteoporosis: year 2000 revision
H. Orimo (2001)
10.1172/JCI116872
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.
R. Balena (1993)
10.1016/S0002-9343(96)00282-3
Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.
J. Tucci (1996)
10.1007/BF02553758
Prediction of vertebral strength by dual photon absorptiometry and quantitative computed tomography
S. Eriksson (2007)
10.1007/PL00004171
Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT Study
H. A. Pols (1999)
10.1001/JAMA.280.24.2077
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
S. Cummings (1998)
Alendronate increases
GY Boivin (2000)
10.1016/S0021-9290(99)00099-8
Femoral strength is better predicted by finite element models than QCT and DXA.
D. Cody (1999)
10.1136/bmj.312.7041.1254
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures
D. Marshall (1996)
10.1016/0268-0033(94)90019-1
In-vitro relationships between vertebral body density, size, and compressive strength the elderly thoracolumbar spine.
S. Edmondston (1994)



This paper is referenced by
10.1007/S12018-009-9066-2
Clinical Tools to Evaluate Bone Strength
S. Manske (2010)
10.1177/2192568219889362
Opportunistic Computed Tomography and Spine Surgery: A Narrative Review
Matthew Shirley (2020)
10.1007/s12018-015-9201-1
FEA to Measure Bone Strength: A Review
K. Engelke (2016)
10.1002/jbmr.347
Association of hip strength estimates by finite‐element analysis with fractures in women and men
S. Amin (2011)
10.1007/s11914-010-0031-2
Biomechanics of Vertebral Fractures and the Vertebral Fracture Cascade
B. Christiansen (2010)
8 Ex Vivo and In Vivo Assessment of Vertebral Strength and Vertebral Fracture Risk Assessed by Dual Energy X-Ray Absorptiometry
K. Imai (2017)
Can 3D measurements obtained by lumbar DXA predict fractures in the dorsal vertebrae?
Mirella López Picazo (2020)
10.1210/jc.2012-2972
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
K. Brixen (2013)
10.21474/IJAR01/4836
IMPACT OF NUTRACEUTICAL STIRRED YOGHURT ON OSTEOPOROSES USING THE OVARIECTOMIZED FEMALE WISTER RAT.
MouniraM Ahmed (2017)
10.1038/bonekey.2014.24
Bisphosphonates and bone quality.
M. Pazianas (2014)
comprehensive assessment of Osteoporosis and Bone Fragility
Jeff L. Fidler (2016)
Transpsoas Interbody Fusion : A Preliminary Report The Effect of Alendronate on Subsidence After Lateral
O'brien (2019)
10.14444/6039
The Effect of Alendronate on Subsidence After Lateral Transpsoas Interbody Fusion: A Preliminary Report
Rahul G. Samtani (2019)
10.1038/s41584-019-0274-y
Next-generation imaging of the skeletal system and its blood supply
A. Grüneboom (2019)
10.14288/1.0319083
Quantifying the response of vertebral bodies to compressive loading using digital image correlation
Hannah M Gustafson (2016)
10.1002/ptr.5218
The Standardized BHH10 Extract, a Combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, Reverses Bone Mass and Metabolism in a Rat Model of Postmenopausal Osteoporosis
Jeong-Eun Huh (2015)
10.1016/j.medengphy.2014.05.001
Influence of 3D QCT scan protocol on the QCT-based finite element models of human vertebral cancellous bone.
Yongtao Lu (2014)
10.1007/s11914-016-0314-3
Tissue-Level Mechanical Properties of Bone Contributing to Fracture Risk
J. Nyman (2016)
10.1016/B978-0-08-055294-1.00093-3
Finite Element Analysis in Bone Research: A Computational Method Relating Structure to Mechanical Function
D. Ruffoni (2011)
10.14245/kjs.2014.11.4.221
Influence of Alendronate and Endplate Degeneration to Single Level Posterior Lumbar Spinal Interbody Fusion
Sang-Mok Kim (2014)
10.5493/wjem.v5.i3.182
Computed tomography-based finite element analysis to assess fracture risk and osteoporosis treatment.
K. Imai (2015)
10.1016/B978-0-12-801238-3.65815-4
X-Ray Based Imaging Methods to Assess Bone Quality
Klaus Engelke (2014)
10.1002/jbmr.3946
Heterogeneity and Spatial Distribution of Intravertebral Trabecular Bone Mineral Density in the Lumbar Spine Is Associated With Prevalent Vertebral Fracture
Jarred Kaiser (2019)
10.1007/s00774-020-01146-6
Evaluations of daily teriparatide using finite-element analysis over 12 months in rheumatoid arthritis patients
K. Ono (2020)
10.1007/s00774-011-0281-9
Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method
K. Imai (2011)
10.1097/BRS.0000000000001175
Prevalence of Poor Bone Quality in Women Undergoing Spinal Fusion Using Biomechanical-CT Analysis
S. Burch (2016)
10.11005/jbm.2017.24.2.117
Longitudinal Change in Trabecular Bone Score during and after Treatment of Osteoporosis in Postmenopausal Korean Women
M. Shin (2017)
10.1016/j.bone.2010.10.159
Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know.
M. Allen (2011)
10.1002/jor.23335
Virtual stress testing of fracture stability in soldiers with severely comminuted tibial fractures
Joseph L. Petfield (2017)
10.3310/hta18110
Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups.
J. Burch (2014)
10.1097/BRS.0b013e3181a55636
Prediction of Vertebral Strength Under Loading Conditions Occurring in Activities of Daily Living Using a Computed Tomography-Based Nonlinear Finite Element Method
T. Matsumoto (2009)
10.1177/0954411914558654
The effect of in situ/in vitro three-dimensional quantitative computed tomography image voxel size on the finite element model of human vertebral cancellous bone
Yongtao Lu (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar